Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Tarsus Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 195
- +36 vs. Q3 2024
- Shares held
- 40.3M
- −2.76M (−6.4%) vs. Q3 2024
- Total value
- $2.23B
- +$814.3M (+57.6%) vs. Q3 2024
- New holders
- 58
- 65 more added
- Sold out
- 22
- 55 more reduced
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $2.98B |
| Q1 2026 | 253 | $3.17B |
| Q4 2025 | 246 | $3.61B |
| Q3 2025 | 220 | $2.67B |
| Q2 2025 | 205 | $1.87B |
| Q1 2025 | 195 | $2.26B |
| Q4 2024 | 195 | $2.23B |
| Q3 2024 | 162 | $1.43B |
| Q2 2024 | 148 | $1.09B |
| Q1 2024 | 157 | $1.43B |
| Q4 2023 | 116 | $652.0M |
| Q3 2023 | 105 | $529.4M |
| Q2 2023 | 92 | $387.3M |
| Q1 2023 | 74 | $252.1M |
| Q4 2022 | 69 | $301.0M |
| Q3 2022 | 75 | $350.8M |
| Q2 2022 | 73 | $291.7M |
| Q1 2022 | 51 | $222.2M |
| Q4 2021 | 43 | $294.2M |
| Q3 2021 | 44 | $277.4M |
| Q2 2021 | 44 | $378.5M |
| Q1 2021 | 41 | $410.4M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Tarsus Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Clearbridge Investments, LLC | 0 | $0 | 0.00% | −191,374−100.0% | Sold out |
| Emerald Advisers, LLC | 0 | $0 | 0.00% | −146,298−100.0% | Sold out |
| Emerald Mutual Fund Advisers Trust | 0 | $0 | 0.00% | −109,692−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −74,957−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −47,060−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −43,380−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −25,900−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −23,199−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −22,493−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −17,684−100.0% | Sold out |
| Ieq Capital, LLC | 0 | $0 | 0.00% | −12,640−100.0% | Sold out |
| Golden State Equity Partners | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −700−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −504−100.0% | Sold out |
| Private Trust Co NA | 0 | $0 | 0.00% | −79−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Ghost Tree Capital, LLC | – | – | – | – | Not filed |
| Raymond James Financial Services Advisors, Inc. | – | – | – | – | Not filed |
| AJOVista, LLC | – | – | – | – | Not filed |